KVP Capital Advisors, LP
Sector Allocation
- Healthcare100.0%$136.2M
AUM History
13fpro.ai/research/fund/kvp-capital-advisors-lp-1858198
Largest positions — Q2 2026
PRAX
$14.4MWHWK
$9.9MERAS
$8.3MTRVI
$7.7MSTRO
$7.5MTNGX
$7.2MMBX
$6.7MPTGX
$6.5MEWTX
$5.4MTNDM
$4.5MIRON
$4.3MSVRA
$3.7MAVBP
$3.5MINSM
$3.0MACHV
$3.0MIDYA
$3.0MOCUL
$2.9MAXSM
$2.9MDSGN
$2.7MUTHR
$2.6M
Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.
13fpro.ai/research/fund/kvp-capital-advisors-lp-1858198
KVP Capital Advisors, LP 13F holdings — Q2 2026
$136.2M portfolio (+1.8% QoQ) · 35 holdings · Q2 2026 13F · top 10 are 57% of the stock portfolio
$14.4M
10.5% of stocks
No changeThis quarter-27.4%Since filed3+ qtrsHeld$9.9M
7.3% of stocks
No changeThis quarter-32.9%Since filed3+ qtrsHeld$8.3M
6.1% of stocks
+34%This quarter-16.1%Since filed2 qtrsHeld$7.7M
5.7% of stocks
No changeThis quarter-31.1%Since filed3+ qtrsHeld$7.5M
5.5% of stocks
No changeThis quarter-58.3%Since filed2 qtrsHeld$7.2M
5.3% of stocks
No changeThis quarter-13.5%Since filed2 qtrsHeld$6.7M
4.9% of stocks
No changeThis quarter-25.0%Since filed3+ qtrsHeld$6.5M
4.8% of stocks
No changeThis quarter-7.3%Since filed3+ qtrsHeld$5.4M
4.0% of stocks
No changeThis quarter-9.3%Since filed3+ qtrsHeld$4.5M
3.3% of stocks
NewThis quarter-18.3%Since filedNew this quarterHeld
All holdings — KVP Capital Advisors, LP (Q2 2026)
35 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.
| # | Company | Held | Source | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 11 | Disc Medicine, Inc. | Healthcare | $4.3M | 3.1% | 58K | — | 3+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 12 | Savara Inc | Healthcare | $3.7M | 2.7% | 605K | — | 3+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 13 | ArriVent BioPharma, Inc. | Healthcare | $3.5M | 2.6% | 102K | New | 1 qtr | AI quality score is Pro: unlock with a free trial | 13F | |
| 14 | INSMED Inc | Healthcare | $3.0M | 2.2% | 28K | — | 3+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 15 | ACHIEVE LIFE SCIENCES, INC. | Healthcare | $3.0M | 2.2% | 462K | — | 3+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 16 | IDEAYA Biosciences, Inc. | Healthcare | $3.0M | 2.2% | 80K | — | 2 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 17 | OCULAR THERAPEUTIX, INC | Healthcare | $2.9M | 2.2% | 300K | — | 2 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 18 | Axsome Therapeutics, Inc. | Healthcare | $2.9M | 2.2% | 12K | -67% | 3+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 19 | Design Therapeutics, Inc. | Healthcare | $2.7M | 2.0% | 185K | New | 1 qtr | AI quality score is Pro: unlock with a free trial | 13F | |
| 20 | UNITED THERAPEUTICS Corp | Healthcare | $2.6M | 1.9% | 4,750 | — | 3+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 21 | Scholar Rock Holding Corp | Healthcare | $2.5M | 1.8% | 45K | — | 3+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 22 | Immix Biopharma, Inc. | Healthcare | $2.4M | 1.7% | 230K | — | 3+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 23 | Viridian Therapeutics, Inc.\DE | Healthcare | $2.3M | 1.7% | 125K | — | 2 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 24 | Mineralys Therapeutics, Inc. | Healthcare | $2.3M | 1.7% | 84K | New | 1 qtr | AI quality score is Pro: unlock with a free trial | 13F | |
| 25 | BRIGHT MINDS BIOSCIENCES INC. | Healthcare | $2.2M | 1.6% | 32K | — | 2 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 26 | $TVTX | Travere Therapeutics, Inc. | Healthcare | $2.2M | 1.6% | 39K | -57% | |||
| 27 | $ZURA | Zura Bio Ltd | Healthcare | $2.2M | 1.6% | 373K | — | |||
| 28 | $ARTV | Artiva Biotherapeutics, Inc. | Healthcare | $1.9M | 1.4% | 200K | New | |||
| 29 | $NKTR | NEKTAR THERAPEUTICS | Healthcare | $1.9M | 1.4% | 27K | — | |||
| 30 | $CMPX | Compass Therapeutics, Inc. | Healthcare | $1.7M | 1.2% | 771K | +54% | |||
| 31 | $CABA | Cabaletta Bio, Inc. | Healthcare | $1.6M | 1.1% | 505K | — | |||
| 32 | $VERA | Vera Therapeutics, Inc. | Healthcare | $1.4M | 1.0% | 33K | — | |||
| 33 | $EOLS | Evolus, Inc. | Healthcare | $1.0M | 0.8% | 150K | New | |||
| 34 | $CELC | Celcuity Inc. | Healthcare | $418K | 0.3% | 4,000 | — | |||
| 35 | $YARW | Yarrow Bioscience, Inc. | Healthcare | $326K | 0.2% | 501K | — |
What changed in Q2 2026
Against the previous quarter's 13F: 6 new, 2 added to, 2 trimmed, 3 sold out. Share-count changes; largest moves by dollar size first.
New positions (6)
first bought this quarter
first bought this quarter
first bought this quarter
$MLYSMineralys Therapeutics, Inc.$2.3M
first bought this quarter
$ARTVArtiva Biotherapeutics, Inc.$1.9M
first bought this quarter
$EOLSEvolus, Inc.$1.0M
first bought this quarter
Added to (2)
Trimmed (2)
Holdings by quarter
Every 13F KVP Capital Advisors, LP has filed, 2 earlier quarters. Pick one to see what it held then.
Is it too late to follow KVP Capital Advisors?
Q2 2026 13F filed with the SEC on Aug 13, 2026. Prices are closing prices as of Oct 26, 2026.
Average quality of KVP Capital Advisors's top 20 holdings: 27/100 (our AI quality score, weighted by position size; 10 of the 20 are scored)
Top 10 since filing
-25.3%
Value-weighted move of the 10 largest stock positions
Turnover
14%
Last quarter
Top 10 weight
57%
Share of the stock portfolio in its 10 largest positions
Held 4+ quarters
0%
Share of portfolio value in positions held a year or more
Highest-quality names it owns(among its 100 largest positions)
The 8 highest-scoring companies in this portfolio are a Pro feature.
How these are measured
- Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
- Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
- Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q4 2025 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
- Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
- Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.
Portfolio Overview
KVP Capital Advisors, LP disclosed 35 positions worth $136.2M in its Form 13F-HR for Q2 2026, led by $PRAX (Praxis Precision Medicines, Inc.) at 10.5% of the equity portfolio, followed by $WHWK and $ERAS. During the quarter the fund opened 6 new positions and exited 3 — including a new stake in $TNDM and a full exit from $TERN. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from KVP Capital Advisors, LP’s Form 13F-HR filing with the SEC under CIK 1858198.
Funds like this
managers whose biggest positions overlap KVP Capital Advisors'sBrowse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
AI-Powered Hedge Fund Analysis: KVP Capital Advisors, LP
13F Pro is an AI hedge fund tracker and stock research platform. For KVP Capital Advisors, LP (SEC CIK: 1858198), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in KVP Capital Advisors, LP's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.